Teva Pharmaceutical Industries (TEVA) Non-Current Debt (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Non-Current Debt for 18 consecutive years, with $14.0 billion the latest figure, recorded in Q1 2026.

• Quarterly Non-Current Debt fell 13.65% year-over-year to $14.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.0 billion (down 13.65% YoY) and the FY2025 annual result came in at $15.0 billion, down 6.35% from the prior year.
• Non-Current Debt fell to $14.0 billion in Q1 2026 per TEVA's latest filing, from $15.0 billion in the prior quarter.
• Over the last five years, Non-Current Debt for TEVA reached as high as $20.8 billion in Q1 2022 and fell as low as $14.0 billion in Q1 2026.
• A 5-year average of $17.5 billion and a median of $16.8 billion in 2025 frame the typical range for Non-Current Debt.
• Annual changes were most pronounced in 2024 — Non-Current Debt decreased 15.68% — and 2025, when it climbed 2.23%.
• Year by year, Non-Current Debt stood at $19.1 billion in 2022, then fell by 4.93% to $18.2 billion in 2023, then decreased by 11.89% to $16.0 billion in 2024, then declined by 6.35% to $15.0 billion in 2025, then fell by 6.48% to $14.0 billion in 2026.
• According to Business Quant data, Non-Current Debt over the past three periods registered $14.0 billion, $15.0 billion, and $16.8 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.